title: Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease.
authors.affiliation: Eli Lilly and Co. Ltd., Lilly Research Centre, Erl Wood Manor, Windlesham Surrey GU20 6PH, United Kingdom.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: O'Neill
authors.forename: Marcus J
authors.initials: MJ
authors.lastname: Messenger
authors.forename: Viktor
authors.initials: V
authors.lastname: Lakics
authors.forename: Tracey K
authors.initials: TK
authors.lastname: Murray
authors.forename: Eric H
authors.initials: EH
authors.lastname: Karran
authors.forename: Philip G
authors.initials: PG
authors.lastname: Szekeres
authors.forename: Eric S
authors.initials: ES
authors.lastname: Nisenbaum
authors.forename: Kalpana M
authors.initials: KM
authors.lastname: Merchant
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D018091:Receptors, AMPA / Q000819:agonists; D033581:Stem Cell Transplantation
chemical_list: D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D018091:Receptors, AMPA